ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
11
04
2023
accepted:
16
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
epublish
Résumé
Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune suppression by synthesising sialoglycans, which act as ligands for Siglec receptors. We report that ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) levels negatively correlate with androgen signalling in prostate tumours. We demonstrate that ST3Gal1 plays an important role in modulating tumour immune evasion through the synthesises of sialoglycans with the capacity to engage the Siglec-7 and Siglec-9 immunoreceptors preventing immune clearance of cancer cells. Here, we provide evidence of the expression of Siglec-7/9 ligands and their respective immunoreceptors in prostate tumours. These interactions can be modulated by enzalutamide and may maintain immune suppression in enzalutamide treated tumours. We conclude that the activity of ST3Gal1 is critical to prostate cancer anti-tumour immunity and provide rationale for the use of glyco-immune checkpoint targeting therapies in advanced prostate cancer.
Identifiants
pubmed: 38448753
doi: 10.1038/s42003-024-05924-0
pii: 10.1038/s42003-024-05924-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276Subventions
Organisme : Prostate Cancer UK
ID : TLD-PF19-002
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Nuhn, P. et al. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur. Urol. 75, 88–99 (2019).
pubmed: 29673712
doi: 10.1016/j.eururo.2018.03.028
Mateo, J. et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur. Urol. 75, 285–293 (2019).
pubmed: 30119985
doi: 10.1016/j.eururo.2018.07.035
Library, W. O. et al. The molecular underpinnings of prostate cancer: impacts on management and pathology practice. Wiley Online Library 241, 173–182 (2017).
Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin. Cancer Res. 25, 3753–3758 (2019).
pubmed: 30787022
doi: 10.1158/1078-0432.CCR-18-4070
Antonarakis, E. S. et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J. Clin. Oncol. 38, 395–405 (2020).
pubmed: 31774688
doi: 10.1200/JCO.19.01638
Bansal, D., Reimers, M. A., Knoche, E. M. & Pachynski, R. K. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers 13, 334 (2021).
pubmed: 33477569
pmcid: 7831137
doi: 10.3390/cancers13020334
Yu, E. Y. et al. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. Eur. Urol. 82, 22–30 (2022).
pubmed: 35397952
doi: 10.1016/j.eururo.2022.02.023
Thoman, M. E. & Salari, K. Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer. Eur. Urol. 82, 31–33 (2022).
pubmed: 35396162
doi: 10.1016/j.eururo.2022.03.016
Yu, E. Y. et al. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. Eur. Urol. 83, 15–26 (2023).
pubmed: 36055895
doi: 10.1016/j.eururo.2022.08.005
Long, X. et al. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. Cell Death Dis. 11, 779 (2020).
pubmed: 32951005
pmcid: 7502080
doi: 10.1038/s41419-020-02973-1
Graff, J. N., Liang, L. W., Kim, J. & Stenzl, A. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 17, 3017–3026 (2021).
pubmed: 34044584
doi: 10.2217/fon-2020-1008
Graff, J. N. et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J. Immunother. Cancer 8, e000642 (2020).
pubmed: 32616555
pmcid: 7333874
doi: 10.1136/jitc-2020-000642
Läubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl. Acad. Sci. USA 111, 14211–14216 (2014).
pubmed: 25225409
pmcid: 4191788
doi: 10.1073/pnas.1409580111
Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med. 14, eabj1270 (2022).
pubmed: 36322632
pmcid: 9812757
doi: 10.1126/scitranslmed.abj1270
Gray, M. A. et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat. Chem. Biol. 16, 1376–1384 (2020).
pubmed: 32807964
pmcid: 7727925
doi: 10.1038/s41589-020-0622-x
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature https://doi.org/10.1038/s41586-019-1456-0 (2019).
Rodriguez, E. et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat. Commun. 12, 1270 (2021).
pubmed: 33627655
pmcid: 7904912
doi: 10.1038/s41467-021-21550-4
Scott, E., Elliott, D. J. & Munkley, J. Tumour associated glycans: A route to boost immunotherapy? Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2019.12.015 (2020).
MacAuley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653–666 (2014).
pubmed: 25234143
pmcid: 4191907
doi: 10.1038/nri3737
Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P. & Ravetch, J. V. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc. Natl. Acad. Sci. USA 118, e2107424118 (2021).
pubmed: 34155121
pmcid: 8256000
doi: 10.1073/pnas.2107424118
Munkley, J. & Scott, E. Targeting Aberrant Sialylation to Treat Cancer. Medicines. https://doi.org/10.3390/medicines6040102 . (2019).
Garnham, R., Scott, E., Livermore, K. E. & Munkley, J. ST6GAL1: A key player in cancer. Oncol. Lett. https://doi.org/10.3892/ol.2019.10458 (2019).
Scott, E. et al. Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer. Int. J. Mol. Sci. 23, 8184 (2022).
pubmed: 35897761
pmcid: 9332126
doi: 10.3390/ijms23158184
Munkley, J. et al. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine https://doi.org/10.1016/j.ebiom.2016.04.018 (2016).
Scott, E. et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. https://doi.org/10.1002/path.6152 (2023).
Hodgson, K. et al. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. (123AD) https://doi.org/10.1038/s41598-023-43019-8 .
Tzeng, S. F. et al. O-Glycosylation–mediated signaling circuit drives metastatic castration-resistant prostate cancer. FASEB Journal 32, 6869–6882 (2018).
doi: 10.1096/fj.201800687
Hoadley, K. A. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048
pmcid: 5957518
doi: 10.1016/j.cell.2018.03.022
Kounatidou, E. et al. A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Res 47, 5634–5647 (2019).
pubmed: 31006810
pmcid: 6582326
doi: 10.1093/nar/gkz286
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
pubmed: 25184630
pmcid: 4201502
doi: 10.1056/NEJMoa1315815
Zhu, Y. et al. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene 39, 6935–6949 (2020).
pubmed: 32989253
pmcid: 7655549
doi: 10.1038/s41388-020-01479-6
Chen, Z. et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc. Natl. Acad. Sci. USA 115, 6810–6815 (2018).
pubmed: 29844167
pmcid: 6042123
doi: 10.1073/pnas.1718811115
Sharp, A. et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Invest. 129, 192–208 (2019).
pubmed: 30334814
doi: 10.1172/JCI122819
Nyquist, M. D. et al. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Rep. 31, 107669 (2020).
pubmed: 32460015
pmcid: 7453577
doi: 10.1016/j.celrep.2020.107669
Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 166, 11428–11436 (2019).
doi: 10.1073/pnas.1902651116
Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
pubmed: 22722839
pmcid: 3396711
doi: 10.1038/nature11125
Brockhausen, I., Wandall, H. H., Hagen, K. G. Ten & Stanley, P. O-GalNAc Glycans. Essent. Glycobiol. https://doi.org/10.1101/GLYCOBIOLOGY.4E.10 (2022).
Hugonnet, M., Singh, P., Haas, Q. & von Gunten, S. The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology. Front Immunol 12, 5495 (2021).
doi: 10.3389/fimmu.2021.799861
Bojar, D. et al. A useful guide to lectin binding: machine-learning directed annotation of 57 unique lectin specificities. Cite This: ACS Chem. Biol 2022, 2993–3012 (2022).
Xie, Y. et al. Determination of the glycoprotein specificity of lectins on cell membranes through oxidative proteomics. Chem. Sci. 11, 9501–9512 (2020).
pubmed: 34094216
pmcid: 8162070
doi: 10.1039/D0SC04199H
Cui, H. X. et al. ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules. Oncol. Rep. 36, 3317–3324 (2016).
pubmed: 27779707
doi: 10.3892/or.2016.5180
Zhang, N., Lin, S., Cui, W. & Newman, P. J. Overlapping and unique substrate specificities of ST3GAL1 and 2 during hematopoietic and megakaryocytic differentiation. https://doi.org/10.1182/bloodadvances.2022007001 (2022).
Pietrobono, S. et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. https://doi.org/10.1038/s41467-020-19575-2 .
Lin, W. Der et al. Sialylation of CD55 by ST3GAL1 facilitates immune evasion in cancer. Cancer Immunol. Res. 9, 113–122 (2021).
pubmed: 33177111
doi: 10.1158/2326-6066.CIR-20-0203
Stanczak, M. A. et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J. Clin Invest. 128, 4912–4923 (2018).
pubmed: 30130255
pmcid: 6205408
doi: 10.1172/JCI120612
Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. https://doi.org/10.1038/s41591-019-0374-x (2019).
Hudak, J. E., Canham, S. M. & Bertozzi, C. R. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. https://doi.org/10.1038/nchembio.1388 (2014).
Jandus, C. et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. https://doi.org/10.1172/JCI65899 . (2014).
Beatson, R. et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol. https://doi.org/10.1038/ni.3552 (2016).
Rodrigues, E. et al. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat. Commun. https://doi.org/10.1038/s41467-020-18907-6 (2020)
Adeniji, O. S. et al. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells. PLoS Pathog. 17, e1010034 (2021).
pubmed: 34762717
pmcid: 8584986
doi: 10.1371/journal.ppat.1010034
Chen, Z. et al. Targeting Neutrophils in Severe Asthma via Siglec-9. Int. Arch. Allergy Immunol. 175, 5–15 (2018).
pubmed: 29306942
doi: 10.1159/000484873
Rodriguez, E. et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat. Commun. 12, 1–14 (2021).
doi: 10.1038/s41467-021-21550-4
Erlandsson, A. et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate 79, 363–369 (2019).
pubmed: 30500076
doi: 10.1002/pros.23742
Siefert, J. C. et al. The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. Mol. Cancer Res. 19, 1778–1791 (2021).
pubmed: 34131070
pmcid: 9398107
doi: 10.1158/1541-7786.MCR-20-0740
Joseph, D. B. et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J. Pathol. 255, 141–154 (2021).
pubmed: 34173975
pmcid: 8429220
doi: 10.1002/path.5751
Dunning, M. J. et al. Mining Human Prostate Cancer Datasets: The “camcAPP” Shiny App. EBioMedicine 17, 5 (2017).
pubmed: 28286059
pmcid: 5360593
doi: 10.1016/j.ebiom.2017.02.022
Siddiqui, S. et al. Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E. J. Biol Chem. 292, 1029–1037 (2017).
pubmed: 27920204
doi: 10.1074/jbc.M116.738351
Smith, B. A. H. et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc. Natl. Acad. Sci. 120, e2215376120 (2023).
pubmed: 36897988
pmcid: 10089186
doi: 10.1073/pnas.2215376120
Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606, 791–796 (2022).
pubmed: 35322234
pmcid: 10294141
doi: 10.1038/s41586-022-04522-6
Qiu, X. et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications 13, 1–17 (2022).
doi: 10.1038/s41467-022-30257-z
Guo, H. et al. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nat. Commun. 12, 1–18 (2021).
doi: 10.1038/s41467-021-27077-y
Consiglio, C. R., Udartseva, O., Ramsey, K. D., Bush, C. & Gollnick, S. O. Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression HHS Public Access. Cancer Immunol. Res. 8, 1215–1227 (2020).
pubmed: 32661092
pmcid: 7484281
doi: 10.1158/2326-6066.CIR-19-0371
Wisnovsky, S. et al. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7. Proc. Natl. Acad. Sci. USA 118, e2015024118 (2021).
pubmed: 33495350
pmcid: 7865165
doi: 10.1073/pnas.2015024118
Büll, C. et al. Probing the binding specificities of human Siglecs by cell-based glycan arrays. Proc. Natl. Acad. Sci. USA 118, e2026102118 (2021).
pubmed: 33893239
pmcid: 8092401
doi: 10.1073/pnas.2026102118
Malaker, S. A. et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc. Natl. Acad. Sci. USA 116, 7278–7287 (2019).
pubmed: 30910957
pmcid: 6462054
doi: 10.1073/pnas.1813020116
Cerami, E. et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov https://doi.org/10.1158/2159-8290.CD-12-0095 (2012).
Scott, E. et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene https://doi.org/10.1038/S41388-023-02604-X (2023).